Nabi buys back more than 3 million shares from Chapman Capital

By Lisa Kerner

Charlotte, N.C., Dec. 7 - Chapman Capital LLC sold 3,084,354 shares of Nabi Biopharmaceuticals' common stock to the company to "take advantage of the extraordinary liquidity provided by the issuer's $65 million open market share repurchase program" and to satisfy the investor's tax planning, according to a schedule 13D filing with the Securities and Exchange Commission.

The shares were sold between Oct. 8 and Dec. 6, priced from $3.58 to $4.09 each.

The reporting persons beneficially own 1,972,944 shares, or 3.2%, of the Boca Raton, Fla., pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.